The California Institute for Regenerative Medicine (CIRM) has recently awarded $25 million dollars to “the first clinical trial based on cells derived from human embryonic stem cells that has been approved by the Federal Drug Administration (FDA).” This clinical trial has been specifically designed to benefit spinal cord injury (SCI) patients. Every year, 12,000 Americans suffer SCIs that permanently alter the quality of their lives.
CIRM has never before funded “stem-cell derived therapy research.” The institute will rely on the Geron Corporation to run this trial.
